SOTIO Broadens Its Phase II Clinical Trial Program in Ovarian Cancer

Oncology, Reproductive Health November 30, 2017 at 9:26 AM 0 comments

Prague, Czech Republic, 28 November, 2017 – SOTIO, a biotechnology company owned by the PPF Group, today announced the enrollment of the first patient to a Phase II study testing DCVAC/OvCa in combination with standard of care chemotherapy for patients with ovarian cancer after first relapse. Based on positive signalsRead More

Orchard Therapeutics Announces Extension of its Collaboration with Manchester University to Include Sanfilippo Syndrome Type B

Uncategorized November 30, 2017 at 9:18 AM 0 comments

Orchard Therapeutics Announces Extension of its Collaboration with Manchester University to Include Sanfilippo Syndrome Type B London & Manchester, UK, 27 November, 2017 – Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announces today that itRead More

UK Health ‘Innovation Hub’ Opens at Dell Medical School

UK Health ‘Innovation Hub’ Opens at Dell Medical School

Innovations November 21, 2017 at 9:09 AM 0 comments

9 November, 2017 – The Association of British Healthcare Industries (ABHI) and the Dell Medical School at The University of Texas at Austin are delighted to announce the establishment of the “ABHI Innovation Hub”. The creation of the Hub, a first for ABHI, will offer UK companies the opportunity to locate themselvesRead More

Introducing EMJ Dermatology 5.1

Introducing EMJ Dermatology 5.1

Dermatology November 2, 2017 at 9:58 AM 0 comments

United Kingdom, November 02, 2017: The European Medical Journal welcomes you to the 2017 edition of EMJ Dermatology, complete with a summary of the 26th European Academy of Dermatology and Venereology (EADV) congress, interviews with members of the highly esteemed EMJ Dermatology Editorial Board, abstracts from the EADV Congress, andRead More

Introducing EMJ Diabetes 5.1

Introducing EMJ Diabetes 5.1

Diabetes October 31, 2017 at 9:51 AM 0 comments

United Kingdom, October 31, 2017: EMJ would like to welcome you to the latest edition of EMJ Diabetes, a journal dedicated to detailing the vital progression in the treatment of diabetes over the last year. A comprehensive review of the key highlights from this year’s 53rd Annual Meeting of theRead More

Introducing EMJ Respriatory 5.1

Introducing EMJ Respriatory 5.1

Respiratory October 26, 2017 at 9:23 AM 0 comments

United Kingdom, October 26, 2017: The European Medical Journal welcomes you to the 2017 edition of the EMJ Respiratory eJournal. This eagerly anticipated publication includes a stimulating summary of the European Respiratory Society (ERS) International Congress 2017, including some of the latest advances from the field in the Congress ReviewRead More

Introducing EMJ Oncology 5.1

Introducing EMJ Oncology 5.1

Oncology October 24, 2017 at 9:14 AM 0 comments

United Kingdom, October 24, 2017: Welcome to this year’s issue of EMJ Oncology, which is filled with the latest developments from the world of cancer studies. Inside, you will find cutting-edge abstracts detailing ongoing research; the latest peer-reviewed articles focussed on the treatment of, detection of, and screening for cancers;Read More

Introducing EMJ Cardiology 5.1

Introducing EMJ Cardiology 5.1

Cardiology October 12, 2017 at 9:21 AM 0 comments

United Kingdom, October 12, 2017: European Medical Journal would like to welcome you to the latest edition of EMJ Cardiology. Packed with the latest research findings and opinions surrounding the human heart, this eJournal brings something truly unique. The 2017 European Society of Cardiology (ESC) annual congress, held in Barcelona,Read More

MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris

Dermatology October 12, 2017 at 9:19 AM 0 comments

First patient dosed in the pivotal Phase 3 trial assessing the safety and efficacy of MC2-01 Cream in US Topline results are expected in Q3 2018 Copenhagen, Denmark, 11 October, 2017 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that first patient has been dosedRead More

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Uncategorized October 10, 2017 at 4:32 PM 0 comments

BEKINDA®1 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan® (rifaximin) and Viberzi® (eluxadoline)2 IBS is one of the most common gastrointestinal disorders,Read More